BioSpace News Archive

Molecular Assemblies, Inc., today announced that it has raised a $25.8 million Series B financing with participation from new investor, Casdin Capital, and all major Series A investors, Agilent Technologies, iSelect Fund, Codexis, LYFE Capital, and Argonautic Ventures.

BioLife Solutions, Inc., a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies and broader biopharma markets, provided additional details on its growth expectations for the Company’s SciSafe® biostorage services platform.

Wugen, Inc. today announced that the first patient has been dosed in a Phase 1/2 trial of WU-CART-007 for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).

Inversago Pharma Inc. announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial.

Agiliti Inc. (NYSE: AGTI) (“Agiliti”) today announced that the company will participate at the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022.

Pear Therapeutics, Inc. today announced data that further underscore the effectiveness of Somryst®, the only FDA-authorized PDT for the treatment of chronic insomnia.

Sonendo, Inc., a dental technology company and creator of the GentleWave System for less invasive and less painful root canal therapy, announced its achievement of a new milestone of 800,000 GentleWave patient procedures.

LinKinVax, a clinical-stage biotech company, is announcing a collaboration with GTP Bioways for the development and production of its second-generation pan-coronavirus vaccine aimed at preventing Covid-19.

Myrtelle Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for its lead clinical-stage gene therapy, rAAV-Olig001-ASPA.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the 32nd Annual Oppenheimer Healthcare Conference.